Introduction {#Sec1}
============

Impact microindentation (IMI), a method to assess tissue-level properties of cortical bone in vivo \[[@CR1], [@CR2]\], is being increasingly used in studies evaluating the contribution of such properties to bone fragility in humans \[[@CR3]--[@CR6]\]. The resistance of cortical bone to indentation, measured as bone material strength index (BMSi), was decreased in individuals with fragility fractures compared with appropriate controls in several studies \[[@CR7]--[@CR10]\]. It is not related to bone mineral density (BMD) values \[[@CR7]--[@CR10]\], but, as recently shown, BMSi most likely assesses subperiosteal bone material properties \[[@CR11]\].

Short-term effects of antiosteoporotic treatments on BMSi have been examined in patients initiating glucocorticoid therapy \[[@CR12]\]. Glucocorticoids induced rapid decreases of BMSi, while treatments prevented this decline or even increased BMSi values within 7 weeks, up to 20 weeks, with no concurrent changes in BMD values. These results strongly suggested that BMSi could detect early, treatment-induced changes in bone material properties in glucocorticoid-treated patients. In addition, increases in BMSi have been reported in postmenopausal women 3 months after a high impact exercise program \[[@CR13]\], and in HIV-infected patients after 1 year treatment with antiretroviral agents \[[@CR14]\] or following gastric bypass surgery in obese subjects with and without type 2 diabetes \[[@CR15]\]. However, the effect of antiosteoporotic treatments on BMSi in patients at increased risk of fractures not receiving glucocorticoids has not been investigated. Moreover, osteoporosis is a chronic disease requiring long-term treatment, and it is currently unknown whether changes in BMSi over time might provide information, additional to those obtained by BMD measurements, in treated individuals.

In the present study, we addressed this question in individuals at increased risk of fractures by measuring BMSi with the handheld IMI device OsteoProbe® before and after treatments given for periods longer than 12 months.

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

Observational study evaluating longitudinal changes in BMSi with antiresorptive agents or vitamin D ± calcium alone in women and men with low bone mass attending the outpatient clinic of the Center for Bone Quality of the Leiden University Medical Center (LUMC) between March 2015 and September 2018.

Patients {#Sec4}
--------

Included in the study were treatment-naive subjects ≥ 18 years with osteopenia or osteoporosis who had an IMI measurement at presentation, were followed by one of the authors (NAD) for at least 1 year and consented to a repeat measurement. Exclusion criteria included any treatment affecting bone metabolism during follow-up---except calcium, vitamin D, bisphosphonates or denosumab---a metabolic bone disease other than osteoporosis, immobilization and local pathologies of the tibia or skin at the site of examination.

Treatment with antiresorptive agents (with vitamin D ± calcium) or vitamin D ± calcium alone was given according to Dutch national guidelines for the management of osteoporosis \[[@CR16]\]. Treatment was initiated with oral bisphosphonates (BP) unless patients had epigastric complaints or did not want to receive oral BP; in these patients, iv BP or denosumab (DMAb) were given according to patients' preference and physician's judgement. All patients were followed at regular intervals in the outpatient clinic according to protocols of the Center for Bone Quality for the different treatment regimens.

The study was approved by the Medical Ethical Committee of the LUMC, and written informed consent was obtained from all individuals included in the study.

Methods {#Sec5}
-------

Detailed medical history, clinical risk factors for fracture, fracture history with documentation of sites and dates of occurrence and information about use of medication were collected at baseline and follow-up visits. A fragility fracture was defined as any low-energy fracture, excluding those of the hands, feet and skull. Reasons and time of discontinuation or change to another antiresorptive agent during follow-up were recorded.

Laboratory measurements {#Sec6}
-----------------------

Serum calcium (albumin-corrected), creatinine and alkaline phosphatase were measured by semiautomated techniques. Plasma intact PTH was measured by immulite 2500 (Siemens Diagnostics, Breda, The Netherlands) and serum 25-hydroxyvitamin D (25-OH D) by the 25-OH-vitamin D TOTAL assay (DiaSorin D.A./N.V., Brussels, Belgium).

Bone mineral density {#Sec7}
--------------------

Areal BMD was measured at the lumbar spine (L1--L4) and the left and right hip by dual-energy X-ray absorptiometry (DXA) with the Hologic QDR 4500 (Hologic Inc., Waltham, MA, USA). Average BMD values of the hip were used in the analysis. NHANES III reference values compatible with reference values of the Dutch population were used to calculate T-scores. Osteopenia and osteoporosis were diagnosed according to WHO criteria.

Vertebral fracture assessment {#Sec8}
-----------------------------

Spine radiographs for the detection of vertebral deformities were performed at baseline in all patients. During follow-up, radiographs were only performed if there was loss of height \> 3 cm or clinical complaints. Radiographs were independently evaluated by two of the authors (NAD and MS) using the semiquantitative method of Genant et al. \[[@CR17]\], and only fractures grade 2 or higher were considered in the analysis.

Bone material strength index {#Sec9}
----------------------------

BMSi was measured in all patients by IMI using the handheld microindenter device (OsteoProbe® RUO, Active Life Scientific, CA, USA) at the midshaft of the tibia. Measurements were performed by two experienced operators (NAD and FM) according to our previously published protocol \[[@CR7], [@CR8], [@CR18], [@CR19]\]. The patient was placed in a decubitus supine position with the tibia in external rotation. The measurement site was defined as the mean distance between the medial malleolus and the distal apex of the patella. After disinfection and local anaesthesia of the skin and periosteum with lidocaine 1%, the test probe was gently inserted in the skin until the bone surface was reached. It was ensured that the test probe was always perpendicular to the bone surface during measurements. The operator was not allowed to check the measurements on the computer screen before these were classified as "well performed", "adequate" or "poorly performed". Measurements were classified as "well performed" when the test probe was exactly perpendicular to the bone surface, as "adequate" when the test probe was within acceptable deviation from the bone surface \[[@CR2]\] and as "poorly performed" when the operator judged that the test probe was not appropriately placed. "Poorly performed" measurements are usually due to slipping of the test probe, moving of the subject's leg, indenting the same spot twice, or failure to place the device perpendicularly to the bone surface and were manually discarded. In addition, the first measurement was systematically discarded since there is often inadequate penetration of the probe through the periosteum. After at least five adequate measurements (range 6 to 15, mean 10.0 ± 1.8 measurements), five additional measurements were performed on a polymethylmethacrylate (PMMA) calibration phantom. BMSi was calculated by the computer software. The operator was not blinded to the patient's treatment, but was blinded to baseline BMSi results, and classification of measurements was done before checking the results on the computer screen. The intraobserver coefficient of variation (CV) was 2.2%, and the interobserver CV was 1.6%.

Statistical analysis {#Sec10}
--------------------

Results are presented as mean ± SD unless otherwise stated. Descriptive statistics were used to describe clinical and laboratory parameters. Between-group differences in baseline characteristics were assessed using a Student's *t* test or Mann-Whitney *U* test and chi-square test or Fisher's exact test for normally and not normally distributed continuous and for categorical variables, respectively. Within-group changes in BMSi and BMD were assessed using a paired *t* test. Normality of the distribution of BMSi and BMD was checked by a Kolmogorov-Smirnov test and visually with histograms. Between-group differences in % changes from baseline to follow-up measurements were assessed by a Student's *t* test. ANCOVA models with % change in BMSi as outcome variable, adjusted for baseline BMSi, BMD and fragility fracture, were used to compare % change in BMSi between groups. Correlations between BMSi and BMD values and between % changes in BMSi and % changes in BMD or duration of treatment were examined by a Pearson's test. To determine independent effects of factors possibly influencing changes in BMSi, a multiple linear regression analysis was used. Age, gender, fragility fracture, baseline BMSi, treatment duration as well as examiner of the first and the second IMI measurement, respectively, were included in the model. A power calculation was performed using a difference of 3.1% in BMSi values. This difference was previously found between patients with and patients without fragility fractures (BMSi 79.9 ± 0.6 vs 82.4 ± 1.0) and considered to be clinically relevant \[[@CR7]\]. The sample size to detect this difference in BMSi from baseline to follow-up with a standard deviation of 5 and power of 0.8 at a significance level of 0.05 was calculated to be 24 per group. All analyses were performed using SPSS software for Windows (version 25.0; SPSS Inc., Chicago, IL, USA). A *p* value \< 0.05 was considered to be statistically significant. Graphs were constructed with Graphpad Prism (version 8.0; Graphpad Software Inc., La Jolla, CA, USA).

Results {#Sec11}
=======

Fifty-four patients were included in the study (Fig. [1](#Fig1){ref-type="fig"}). These were 34 women and 20 men with median age 58.0 years (IQR 48.5--63.3 years). Thirty-one patients had osteoporosis (57.4%) and 23 had osteopenia (42.6%); 23 patients (7 men) had sustained one or more fragility fractures (11 vertebral, 2 hip, 14 non-hip/non-vertebral) at the time of the first IMI measurement (Table [1](#Tab1){ref-type="table"}). Mean time to second measurement was 23.1 ± 6.6 months.Fig. 1Patient flowchartTable 1Baseline characteristics of 54 patientsCharacteristicsAll patientsTreatmentControl*p* value*n*543024Age, years58.0 ± 1.859.0 ± 1.855.0 ± 3.20.16Male/female20/348/2212/120.11BMI, kg/m^2^24.2 ± 3.624.0 ± 3.424.5 ± 4.00.67Smoking, *n*7610.12Alcohol use ≥ 3 U/d, *n*5230.65Previous fragility fracture, *n* (%)23 (42.6)19 (63.3)4 (16.7)0.001Hip fracture, *n* (%)2 (3.7)2 (6.7)0 (0.0)0.50NHNV fracture, *n* (%)14 (25.9)10 (33.3)4 (16.7)0.17Vertebral fracture, *n* (%)11 (20.4)11 (40.0)0 (0.0)0.001Calcium^a^, mmol/L2.32 ± 0.082.34 ± 0.082.31 ± 0.080.11Creatinine^b^, umol/L76.1 ± 15.074.0 ± 13.878.8 ± 16.20.2425-OH D^c^, nmol/L80.9 ± 27.778.7 ± 29.083.6 ± 26.40.52PTH^d^, pmol/L3.5 ± 1.33.6 ± 1.63.2 ± 0.90.13LS-BMD T-score− 2.1 ± 0.8− 2.3 ± 0.7− 1.9 ± 0.90.10FN-BMD T-score− 1.7 ± 0.7− 1.9 ± 0.7− 1.5 ± 0.60.08TH-BMD T-score− 1.3 ± 0.7− 1.5 ± 0.6− 1.1 ± 0.80.026BMSi80.6 ± 4.379.3 ± 4.182.2 ± 4.10.014*NHNV*, Non-hip/non-vertebral; *BMD*, bone mineral density; *LS*, lumbar spine; *FN*, femoral neck; *TH*, total hip; *BMSi*, bone material strength index. Values are expressed as mean ± SD. Age is expressed as median ± SEM. *p* values are displayed for treatment vs control^a^Calcium (albumin-corrected) reference range, 2.15--2.55 mmol/L^b^Creatinine reference range, 64--104 umol/L for males; 49--90 umol/L for females^c^25-OH vitamin D reference range, 50--250 nmol/L^d^PTH reference range, 0.7--8.0 pmol/L

Baseline characteristics of patients who were excluded from the study, either because they were referred to their general practitioners, were followed by other physicians in our centre or were lost to follow-up (Fig. [1](#Fig1){ref-type="fig"}), were not different from those of the included patients; age 56.2 ± 14.2 vs 55.3 ± 13.0 years, *p* = 0.637; female gender 59.5% vs 63.0%, *p* = 0.665; prevalent fragility fractures 47.7% vs 42.6%, *p* = 0.500; BMSi 80.7 ± 5.6 vs 80.6 ± 4.3, *p* = 0.894.

Of the 54 patients included in the analysis, 30 started antiresorptive therapy after a median of 4 days following the first IMI measurement (treatment group); 23 patients received BPs (16 oral, 7 iv) and 7 DMAb. Twenty-four patients received vitamin D ± calcium alone (control group) (Table [1](#Tab1){ref-type="table"}). Patients in the treatment group had sustained significantly more fragility fractures compared with those of the control group (25 vs 4, *p* \< 0.01), due mainly to the higher prevalence of vertebral fractures in the former group (14 vs 0, *p* \< 0.01).

Bone mineral density {#Sec12}
--------------------

In the treatment group, 20 patients had osteoporosis (T-score ≤ −2.5) and 10 had osteopenia (T-score between − 2.5 and − 1.0); in the control group, 11 patients had osteoporosis and 13 had osteopenia (*p* = 0.124 between the two groups). Lumbar spine (LS) BMD was lower in the treatment group, but the difference between the two groups was not significant (0.81 ± 0.08 vs 0.86 ± 0.10 g/cm^2^, *p* = 0.06); femoral neck (FN) BMD and total hip (TH) BMD were significantly lower in the treatment group (FN 0.66 ± 0.09 vs 0.70 ± 0.09 g/cm^2^, *p* = 0.041; TH 0.77 ± 0.10 vs 0.84 ± 0.12 g/cm^2^, *p* = 0.016).

Antiresorptive treatment was associated with significant increases in LS-BMD (6.3 ± 5.3%) and TH-BMD (1.1 ± 2.9%) but not in FN-BMD (1.2 ± 3.6%) (Fig. [2](#Fig2){ref-type="fig"}). In the control group, LS-BMD did not change significantly during follow-up (− 1.3 ± 3.6%,), while hip BMD decreased significantly at both measured sites (FN-BMD − 2.7 ± 4.6%, TH-BMD − 2.4 ± 2.9%) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Mean (±SD) percentage changes in bone mineral density (BMD) at follow-up compared with baseline in the treatment (black bars) and control group (grey bars) at the lumbar spine (LS), femoral neck (FN) and total hip (TH). \*Significantly different from baseline, *p* \< 0.05 and \*\**p* \< 0.001

Bone material strength index {#Sec13}
----------------------------

Consistent with our previous studies, baseline BMSi values of all studied patients were not associated with baseline BMD values at any site (LS *r* = − 0.072, *p* = 0.617; FN *r* = 0.067, *p* = 0.631; TH *r* = 0.048, *p* = 0.728) and were significantly lower in patients with fragility fractures compared with those without (78.5 ± 3.0 vs 82.1 ± 4.5, *p* = 0.002).

### Changes during follow-up {#Sec14}

Baseline BMSi values of the treatment group were significantly lower than those of the control group (Table [1](#Tab1){ref-type="table"}) and increased significantly by 4.0 ± 5.2% to values similar to those of the control group at baseline (from 79.3 ± 4.1 to 82.4 ± 4.3, *p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). The increase in BMSi with antiresorptive treatment was inversely related with baseline BMSi (*r* = − 0.432, *p* = 0.017) (Fig. [4](#Fig4){ref-type="fig"}) but not with the duration of treatment (*r* = 0.089 *p* = 0.639) or with the BMD changes (LS *r* = − 0.076, *p* = 0.712; FN *r* = 0.266, *p* = 0.155; TH *r* = − 0.031, *p* = 0.870). In contrast, in the control group, BMSi values decreased during the period of observation but not significantly (from 82.2 ± 4.1 to 81.5 ± 5.2, *p* = 0.353; − 0.7 ± 3.9%) (Fig. [3](#Fig3){ref-type="fig"}). The difference in % BMSi changes between the two groups was significant, *p* \< 0.001 (also after adjusting for baseline BMSi (*p* = 0.004), baseline BMD (*p* = 0.007) and prevalent fragility fractures (*p* = 0.016)).Fig. 3Bone material strength index (BMSi) in patients with antiresorptive treatment (treatment) and those without antiresorptive treatment (control) at baseline (BL) and follow-up (FU). Data are shown in box-whisker plots and statistical differences are displayed for BMSi. Boxes indicate median and interquartile range. Bars indicate minimum and maximum values. \*\**p* \< 0.001Fig. 4Relationship between bone material strength index (BMSi) at baseline and % BMSi change from baseline to follow-up in 30 patients treated with antiresorptive agents. *r* = − 0.432, *p* = 0.017. Absence of change in BMSi is indicated by the dashed line

In both BP- and DMAb-treated patients for the whole observation period, BMSi increased significantly (BP from 80.1 ± 4.6 to 82.5 ± 4.4 (3.1 ± 5.6%), *p* = 0.037; DMAb from 78.1 ± 3.1 to 84.2 ± 4.3 (7.8 ± 3.1%), *p* = 0.001). The percentage increase in BMSi was higher in the DMAb-treated patients (*p* = 0.014), but after adjusting for baseline BMSi, the difference between the two treatments was not significant anymore (7.1 ± 4.8% vs 3.4 ± 4.7%, *p* = 0.104). Numbers however were small.

Fractures {#Sec15}
---------

During the period of observation, there were no fragility fractures in the treatment group while two patients of the control group sustained fragility fractures. In the first patient, a decline of BMSi by 8.5% was documented 17 months before a humerus fracture; the corresponding decreases of LS-, FN- and TH-BMD were − 2.2%, − 1.3% and − 2.7% to T-scores of − 1.5, − 0.9 and − 0.4, respectively. New assessment revealed no causes of secondary osteoporosis. The second patient sustained a Weber B ankle fracture 18 months after the second measurement that showed an 8.9% decline of BMSi; the corresponding decreases of LS-, FN- and TH-BMD were − 4.8%, − 7.0% and − 4.3% to T-scores of − 2.2, − 1.7 and − 0.4, respectively.

Discussion {#Sec16}
==========

This study demonstrates that treatment with BPs and DMAb, given for a mean period of 2 years, increases BMSi values, measured by impact microindentation, in patients with low bone mass and increased risk of fracture. The values of BMSi reached with treatment were not different from baseline values of the patients of the control group as well as from those previously reported in patients with low bone mass without fractures \[[@CR7], [@CR8]\]. The magnitude of these changes was, however, different among treated patients and depended on baseline values with larger increases observed in the patients with lower baseline values. Our results are, therefore, in agreement with those obtained after short-term treatment of patients receiving glucocorticoids \[[@CR12]\]. The pattern of BMSi changes by antiresorptive therapy was further similar to that observed after treatment of HIV-infected patients with antiretroviral agents or following gastric bypass surgery in obese subjects with and without type 2 diabetes \[[@CR14], [@CR15]\].

The increases in BMSi values observed in our and other studies \[[@CR12], [@CR14], [@CR15]\] were not related with changes in BMD illustrating, in a different setting, the independence of measurements of bone material properties from those of mineral density as also reported previously in cross-sectional studies \[[@CR7]--[@CR10], [@CR20]--[@CR28]\]. We recently confirmed the lack of a relationship between BMSi and BMD by direct measurements of bone mineral density distribution (BMDD) by quantitative backscattered electron imaging (qBEI) in whole bone tissue in iliac crest bone biopsies obtained concurrently with BMSi measurements in patients with a wide range of BMD \[[@CR11]\].

In the present study, patients treated with antiresorptive agents had lower baseline BMSi values and a higher number of fragility fractures than those treated with vitamin D ± calcium alone. Notably, BMSi was not considered in treatment decision that was based on conventional tools to assess fracture risk. Guidelines for use of BMSi measurements by OsteoProbe® in clinical practice are not yet available, and their value is investigated in research settings, as in our study. Results, however, strengthen the notion that measurements of BMSi may be a useful addition to currently available tools for the assessment of fracture risk.

The results of our study and that of Mellibovsky et al. in glucocorticoid-treated patients \[[@CR12]\] demonstrate that BMSi, measured by IMI, increases by treatments of osteoporosis. We show, in addition, that these increases are not related to treatment duration and appear to have a plateau which is essentially not different from normal values and might represent the maximum value that can be achieved with treatment. This plateau was reached with both DMAb and BP, and the significantly higher increases in BMSi values with DMAb are likely due to the lower baseline BMSi values of patients treated with this more potent agent, but numbers were small.

The mechanism responsible for the increase in BMSi by antiresorptives has not yet been established. We recently showed that BMSi measured by OsteoProbe® is significantly associated with bone material properties, measured by Raman spectroscopy, of subperiosteal bone in patients with different skeletal disorders and a wide range of BMD, with or without fractures \[[@CR11]\]. We have now extended this study, and we measured material properties of the whole cortex of these biopsies by Fourier transform infrared imaging (FTIRI), a spectroscopic method more suitable for the measurement of compositional bone changes in large areas (manuscript in preparation). In this analysis, BMSi values were strongly associated, *p* \< 0.01, with the mineral to matrix ratio (MM), the most widely measured bone material property, that, differently from other measurements of mineral density, directly measures and accounts for the amount of organic matrix in the volume analysed \[[@CR29]\]. In rodents, MM correlates with ash weight and is directly proportional to bending stiffness and failure moment being superior to total mineral density, measured by micro-CT, in predicting bone strength \[[@CR30], [@CR31]\]. Bisphosphonates and hormone replacement therapy given for 1 to 3 years to animals or humans increased significantly spectroscopically measured MM \[[@CR32]--[@CR35]\]. Moreover, inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) by osteoprotegerin (OPG) significantly increased MM in genetically modified ovariectomized mice to levels of wild-type animals (*E. Paschalis* personal communication). It may, therefore, be that BMSi measurements capture the observed increases in MM by antiresorptive therapies. Notably, prolongation of treatment with bisphosphonate, as in the FLEX study with alendronate, is not associated with continuous increase in MM \[[@CR36]\] indicating that the amount of mineral taken up by the matrix in non-pathological mineralisation is limited, or self-regulated; this finding is similar to the observed plateau of bone matrix mineralisation between 5 and 10 years treatment of patients with osteoporosis with denosumab \[[@CR37]\] and may explain the lack of further increases in BMSi values when these reach normal levels shown in our study.

Notably, patients on antiresorptive treatments in our study sustained no fractures, whereas fractures occurred only in two patients in the control group. These two patients showed significant decreases in BMSi values (− 8.5% and − 8.9%) during follow-up, whereas the corresponding decreases in BMD were variable and ranged between − 1.3% and − 7.0%. Moreover, in a cross-sectional study of postmenopausal women on long-term treatment with bisphosphonates (4 to 14 years) BMSi values were significantly lower in women with incident fractures compared with those without fractures \[[@CR28]\]. Thus, IMI measurements may not only be a useful, complementary investigation in the assessment of fracture risk but may also provide additional long-term information about the effects of treatments on bone material properties and their association to bone fragility. This needs, however, to be confirmed in appropriately designed studies.

A limitation of the study is the inclusion of only patients followed by one of the authors. However, baseline characteristics of patients who had a baseline measurement but were not included in the study did not differ from those of patients reported here and treatment protocols were the same. Moreover, all measurements were performed by two experienced investigators that minimized intra- and interobserver variability, a known limitation of the application of IMI technique \[[@CR1], [@CR2], [@CR6]\].

In summary, our study, the first to investigate longitudinal changes in BMSi with antiosteoporotic treatments in patients with low bone mass and increased fracture risk, demonstrates that IMI can capture BMD-independent, treatment-induced increases in BMSi, the magnitude of which depends on pre-treatment values.
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